A new study has found that published cost-effectiveness claims related to cardiovascular therapies tend to assume a mortality benefit, without clear support from gold standard clinical trial data.
The cost-effectiveness analysis is an important tool for assessing the costs and clinical outcomes of an innovation, and is used to support market access and pricing discussions.
Conducted by the Partnership for Health Analytic Research, the study found that, due to a lack of available data on mortality, 88% of such papers did not use direct, statistically significant randomized controlled trial evidence to support the mortality benefit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze